Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm Phase II Study to Assess the Safety, Tolerability, and Efficacy of Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia (GMALL-Isatuximab)

NCT06648889 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT06648889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06648889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm Phase II Study to Assess the Safety, Tolerability, and Efficacy of Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia (GMALL-Isatuximab)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Recruiting
Start date
October 22, 2024
Completion date
June 30, 2030
Enrollment
28 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

t-all